Summary

Eligibility
for males ages 18-45 (full criteria)
Healthy Volunteers
healthy people welcome
Location
at UCLA
Dates
study started
estimated completion
Principal Investigator
by Cherie Blair (ucla)

Description

Summary

This clinical trial aims to investigate the effects of a decline in methamphetamine use on rectal inflammatory cytokine levels, substance use contexts, and HIV/STI risk behavior. This clinical trial also seeks to evaluate joint effects of methamphetamine use and rectal gonorrhea/chlamydia infection on rectal inflammatory cytokine levels. The proposed trial will consist of 40 HIV uninfected MSM, half with rectal gonorrhea/chlamydia infection at enrollment (n=20), with methamphetamine use disorder that will receive contingency management for methamphetamine reduction. Following baseline measurement, participants will be observed over the course of 8 weeks, where participants will complete behavioral surveys, provide urine for drug testing, and rectal samples for measurement of rectal inflammatory cytokine levels.

Official Title

Effects of Methamphetamine Use on Risk Behavior, Systemic and Mucosal Inflammation, and Sexually Transmitted Infection (STI)/HIV Risk Among Men Who Have Sex With Men

Keywords

Methamphetamine-dependence Rectal Gonorrhea Rectal Chlamydia Gonorrhea Inflammation Contingency Management

Eligibility

You can join if…

Open to males ages 18-45

  • Cisgender male
  • 18 to 45 years of age
  • HIV-negative
  • Understand written and spoken English
  • condomless anal intercourse with HIV-positive or status unknown partner in past 90 days
  • Meet DSM-5 criteria for methamphetamine use disorder
  • Positive urine toxicology screen for MA metabolites at study entry
  • Negative syphilis screen
  • Negative rectal GC/CT screen (n=20) or Positive rectal GC and/or CT screen (n=20)
  • Able to provide written informed consent and willing/able to complete study visits.

You CAN'T join if...

  • Reports current treatment for another substance use disorder
  • Positive test for opioids, cocaine, and/or hallucinogens
  • Treatment for gonorrhea and/or chlamydia infection in past 3 months
  • Presence of a condition that in the opinion of the investigator would compromise the safety of the patient or the quality of the data

Location

  • UCLA Vine Street Clinic accepting new patients
    Los Angeles California 90038 United States

Lead Scientist at University of California Health

  • Cherie Blair (ucla)
    HS Clinical Instructor, Medicine. Authored (or co-authored) 4 research publications

Details

Status
accepting new patients
Start Date
Completion Date
(estimated)
Sponsor
University of California, Los Angeles
ID
NCT05162391
Study Type
Interventional
Participants
Expecting 40 study participants
Last Updated